Cancer Drugs Cost Patients And Payers 189% More In Hospitals vs. Physician Offices – IMS
This article was originally published in The Pink Sheet Daily
Differences in covered costs were greatest for Avastin, Lemtrada, Perjeta and Rituxan, among 10 commonly prescribed drugs studied, IMS found. Patient cost sharing was an average $134 higher per dose in hospitals.
You may also be interested in...
In an effort to support its claim that the 340B drug discount program is being used by hospitals to generate profits, the Biotechnology Industry Organization released a study finding use of 340B drugs at physician-based oncology practices grew significantly after they were acquired by hospitals.
A group supported by drug manufacturers and pharmacy benefit managers – the Alliance for Integrity and Reform of 340B – is pushing Congress to alter how hospitals qualify for discounted drugs under the 340B program.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.